Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Si reside en California y compró ciertos productos para perros Cosequin® para uso personal entre el 3 de mayo de 2016 y el 6 de mayo de 2022, es posible que cumpla con los requisitos para recibir beneficios de una Conciliación de demanda colectiva
  • USA - English


News provided by

United States District Court for the Central District of California

Mar 09, 2026, 12:00 ET

Share this article

Share toX

Share this article

Share toX

LOS ANGELES, 9 de marzo de 2026 /PRNewswire-HISPANIC PR WIRE/ --

Un tribunal autorizó este aviso. No se trata del ofrecimiento de un abogado.

Se ha llegado a una conciliación de $11.5 millones en una demanda colectiva contra Nutramax Laboratories, Inc. y Nutramax Laboratories Veterinary Sciences, Inc. (en conjunto, los "Demandados"). La demanda afirma que los Demandados tergiversaron los beneficios y la eficacia de ciertos suplementos caninos bajo el nombre Cosequin®, tanto en la publicidad como en su empaque. Los Demandados rechazan todas las alegaciones de culpa, acto indebido o responsabilidad presentadas por los Demandantes. El Tribunal no ha determinado que se haya cometido alguna falta indebida.

El propósito de este Aviso es proporcionar información sobre esta Conciliación y explicar sus derechos y opciones.

¿Quién está incluido? El Grupo se define como todas las personas que residen en California y que compraron los siguientes Productos Cosequin® caninos para uso personal: Tabletas masticables Cosequin® DS Maximum Strength; Tabletas masticables Cosequin® DS Maximum Strength Plus MSM; Tabletas masticables Cosequin® Maximum Strength Plus MSM; Tabletas masticables Cosequin® with MSM; Masticables blandos Cosequin® DS Maximum Strength Plus MSM; Masticables blandos Cosequin® Maximum Strength Plus MSM y Masticables blandos Cosequin® with MSM entre el 3 de mayo de 2016 y el 6 de mayo de 2022. "Productos para uso personal" se refiere a los productos comprados para uso doméstico de un animal o mascota, y no para reventa u otro fin comercial.

Qué estipula la conciliación? Si usted es Miembro del Grupo de Demandantes, puede presentar un Formulario de Reclamo en www.CosequinCASettlement.com o por correo postal con matasellos no posterior al 21 de julio de 2026, para ser elegible para un Pago de Conciliación de hasta $25 por unidad de Productos Cosequin® comprados entre el 3 de mayo de 2016 y el 6 de mayo de 2022, hasta un máximo de $150. Cada Hogar está limitado y solo puede presentar un único Formulario de reclamación. A los efectos de la Conciliación, Hogar se define como todas las personas que viven en la misma dirección física.

El fondo de la conciliación de $11.5 millones se utilizará para cumplir con las obligaciones monetarias para con los Miembros del Grupo, pagar todos los pagos de la conciliación a los mismos, las adjudicaciones de servicios y la Asignación de Honorarios y Gastos ordenada por el Tribunal después de la presentación de la Solicitud de Honorarios y Gastos por el Abogado del Grupo. Si el monto total de los Reclamos válidos es superior a lo que queda del Fondo de la Conciliación después de eliminar los Honorarios y costos de abogados y las Adjudicaciones por servicios, entonces el pago de la Conciliación para cada Miembro del Grupo se reducirá de manera prorrateada (un término legal que significa igual).

Encontrará más información disponible en el Acuerdo de Conciliación o en el Aviso en formato largo disponible en el sitio web.

Otras opciones. Si no desea estar obligado legalmente por la Conciliación, debe enviar una solicitud de exclusión con matasellos no posterior al 22 de junio de 2026. Si no se excluye, renunciará al derecho de demandar y eximirá a los Demandados y a las Partes eximidas de los reclamos legales planteados en esta demanda. Si no se excluye, puede oponerse a la Conciliación y/o a la Asignación de honorarios y gastos de abogados y a las adjudicaciones de servicios antes del 22 de junio de 2026. El Aviso en Formulario detallado que consta en el Sitio web de la Conciliación explica cómo hacer para presentar una exclusión u objeción. Si no hace nada, no obtendrá ningún Pago de la Conciliación y estará obligado por la Conciliación y cualquier sentencia y orden. El Tribunal celebrará una Audiencia de Aprobación Definitiva el 13 de agosto de 2026 para considerar si aprueba la Conciliación, los honorarios de los abogados del Grupo de hasta el 33 % del Fondo de la Conciliación y los costos y cualquier objeción. Usted o su abogado pueden asistir y solicitar comparecer en la audiencia si usted objeta, pero no están obligados a hacerlo.

Este aviso es un resumen. Obtenga más información sobre la Conciliación en www.CosequinCASettlement.com o llame al número gratuito 1-888-899-7783.

FUENTE Tribunal de Distrito de los Estados Unidos para el Distrito Central de California

URL: www.CosequinCASettlement.com

21%

more press release views with 
Request a Demo

Modal title

Also from this source

If you reside in California and purchased certain dog Cosequin® Products for personal use between May 3, 2016, and May 6, 2022, you may be eligible to receive benefits from a class action Settlement

A Court authorized this Notice. This is not a solicitation from a lawyer. A $11.5 million settlement has been reached in a class action lawsuit...

Third-party payors ("TPPs") in the U.S. that purchased, paid for, and/or reimbursed all or any portion of the price for Actos, ActosPlus MET, ActosPlus MET XR, Duetact, and/or Oseni, for five or more independent prescriptions, between July 1, 1999 and September 17, 2010, for purposes other than resale, may have their rights affected by a class action lawsuit

What is the lawsuit about? A National Third-Party Payor ("TPP") Class has been certified in a class action lawsuit against Defendant Takeda...

More Releases From This Source

Explore

Hispanic

Hispanic

Diversity, Equity & Inclusion

Diversity, Equity & Inclusion

Legal Issues

Legal Issues

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2026 Cision US Inc.